Rimcazole: Difference between revisions

Page 1
Page 2
Content deleted Content added
SVG
IB autocalculates MW
 
(37 intermediate revisions by 23 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{cs1 config|name-list-style=vanc}}
{{Drugbox
{{Drugbox
| Verifiedfields = changed
|IUPAC_name = 9-{3-[(3''R'',5''S'')-3,5-dimethylpiperazin-1-yl]propyl}-9''H''-carbazole
| Watchedfields = changed
| verifiedrevid = 387268762
| IUPAC_name = 9-{3-[(3''R'',5''S'')-3,5-Dimethylpiperazin-1-yl]propyl}-9''H''-carbazole
| image = Rimcazole.svg
| image = Rimcazole.svg

| CAS_number=75859-04-0
<!--Clinical data-->
| ATC_prefix=none
| ATC_suffix=
| tradename =
| pregnancy_category =
| ATC_supplemental=
| legal_status =
| PubChem=53389
| routes_of_administration =
| DrugBank=

<!--Pharmacokinetic data-->
| bioavailability =
| metabolism =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 75859-04-0
| ATC_prefix = none
| PubChem = 53389
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = C3N1PS8CX1
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 275707
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 48221

<!--Chemical data-->
| C=21 | H=27 | N=3
| C=21 | H=27 | N=3
| smiles = C[C@@H]1CN(C[C@@H](N1)C)CCCN2C3=CC=CC=C3C4=CC=CC=C42
| molecular_weight = 321.459
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| bioavailability=
| StdInChI = 1S/C21H27N3/c1-16-14-23(15-17(2)22-16)12-7-13-24-20-10-5-3-8-18(20)19-9-4-6-11-21(19)24/h3-6,8-11,16-17,22H,7,12-15H2,1-2H3/t16-,17+
| metabolism =
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| elimination_half-life=
| StdInChIKey = GUDVQJXODNJRIJ-CALCHBBNSA-N
| excretion =
| pregnancy_category =
| legal_status =
| routes_of_administration=
}}
}}


'''Rimcazole''' is an [[Receptor antagonist|antagonist]]<ref>Gilmore DL, Liu Y, Matsumoto RR. Review of the pharmacological and clinical profile of rimcazole. CNS Drug Reviews. 2004 Spring;10(1):1-22.</ref> of the [[sigma receptor]].<ref>{{cite journal |author=Eaton MJ, Lookingland KJ, Moore KE |title=The sigma ligand rimcazole activates noradrenergic neurons projecting to the paraventricular nucleus and increases corticosterone secretion in rats |journal=Brain Res. |volume=733 |issue=2 |pages=162–6 |year=1996 |pmid=8891298 |doi=10.1016/0006-8993(96)00290-9}}</ref> Sigma receptors are thought to be involved in the drug [[psychosis]] that can be induced by some drugs such as [[Phencyclidine|PCP]] and [[cocaine]], and rimcazole was originally researched as a potential [[antipsychotic]] with a different mechanism of action to traditional antipsychotic drugs. Trials proved inconclusive and rimcazole was not pursued for this application, but other sigma antagonists continue to be researched for a variety of potential applications.<ref> Volz HP, Stoll KD. Clinical trials with sigma ligands. Pharmacopsychiatry. 2004 Nov;37 Suppl 3:S214-20. </ref> Rimcazole has been shown to reduce the effects of cocaine,<ref>Katz JL, Libby TA, Kopajtic T, Husbands SM, Newman AH. Behavioral effects of rimcazole analogues alone and in combination with cocaine. European Journal of Pharmacology. 2003 May 9;468(2):109-19.</ref> and analogues of rimcazole have been shown to be highly effective at blocking the [[convulsions]] caused by cocaine [[overdose]] in animal models.<ref>Matsumoto RR, Hewett KL, Pouw B, Bowen WD, Husbands SM, Cao JJ, Hauck Newman A. Rimcazole analogs attenuate the convulsive effects of cocaine: correlation with binding to sigma receptors rather than dopamine transporters. Neuropharmacology. 2001 Dec;41(7):878-86.</ref>
'''Rimcazole''' is an [[Receptor antagonist|antagonist]]<ref name="Gilmore_2004">{{cite journal | vauthors = Gilmore DL, Liu Y, Matsumoto RR | title = Review of the pharmacological and clinical profile of rimcazole | journal = CNS Drug Reviews | volume = 10 | issue = 1 | pages = 1–22 | date = 2004 | pmid = 14978511 | pmc = 6741722 | doi = 10.1111/j.1527-3458.2004.tb00001.x }}</ref> of the [[sigma receptor]]<ref>{{cite journal | vauthors = Eaton MJ, Lookingland KJ, Moore KE | title = The sigma ligand rimcazole activates noradrenergic neurons projecting to the paraventricular nucleus and increases corticosterone secretion in rats | journal = Brain Research | volume = 733 | issue = 2 | pages = 162–166 | date = September 1996 | pmid = 8891298 | doi = 10.1016/0006-8993(96)00290-9 | s2cid = 42885767 }}</ref> as well as a [[dopamine reuptake inhibitor]].<ref>{{cite journal | vauthors = Husbands SM, Izenwasser S, Loeloff RJ, Katz JL, Bowen WD, Vilner BJ, Newman AH | title = Isothiocyanate derivatives of 9-[3-(cis-3,5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole): irreversible ligands for the dopamine transporter | journal = Journal of Medicinal Chemistry | volume = 40 | issue = 26 | pages = 4340–4346 | date = December 1997 | pmid = 9435903 | doi = 10.1021/jm9705519 }}</ref> Sigma receptors are thought to be involved in the drug [[psychosis]] that can be induced by some drugs such as [[phencyclidine]] and [[cocaine]], and rimcazole was originally researched as a potential [[antipsychotic]] with a different mechanism of action to traditional antipsychotic drugs. Trials proved inconclusive and rimcazole was not pursued for this application, but other sigma antagonists continue to be researched for a variety of potential applications.<ref name="pmid15547788">{{cite journal | vauthors = Volz HP, Stoll KD | title = Clinical trials with sigma ligands | journal = Pharmacopsychiatry | volume = 37 | issue = Suppl 3| pages = S214–S220 | date = November 2004 | pmid = 15547788 | doi = 10.1055/s-2004-832680 | s2cid = 260238757 }}</ref> Rimcazole has been shown to reduce the effects of cocaine,<ref name="pmid12742518">{{cite journal | vauthors = Katz JL, Libby TA, Kopajtic T, Husbands SM, Newman AH | title = Behavioral effects of rimcazole analogues alone and in combination with cocaine | journal = European Journal of Pharmacology | volume = 468 | issue = 2 | pages = 109–119 | date = May 2003 | pmid = 12742518 | doi = 10.1016/s0014-2999(03)01638-8 }}</ref> and analogues of rimcazole have been shown to be highly effective at blocking the [[convulsions]] caused by cocaine [[overdose]] in animal models.<ref name="pmid11684152">{{cite journal | vauthors = Matsumoto RR, Hewett KL, Pouw B, Bowen WD, Husbands SM, Cao JJ, Newman AH | title = Rimcazole analogs attenuate the convulsive effects of cocaine: correlation with binding to sigma receptors rather than dopamine transporters | journal = Neuropharmacology | volume = 41 | issue = 7 | pages = 878–886 | date = December 2001 | pmid = 11684152 | doi = 10.1016/s0028-3908(01)00116-2 | s2cid = 44328858 }}</ref>


==References==
== References ==
{{Reflist|2}}
<references/>


{{Monoamine reuptake inhibitors}}
{{biochem-stub}}
{{Sigma receptor modulators}}
{{pharm-stub}}


[[Category:Piperazines]]
[[Category:Piperazines]]
[[Category:Carbazoles]]
[[Category:Carbazoles]]
[[Category:Dopamine reuptake inhibitors]]
[[Category:Sigma antagonists]]
[[Category:Anticonvulsants]]

{{nervous-system-drug-stub}}